Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study
Andrew Menzies‐Gow, Claire McBrien, Bindhu Unni, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 63-78
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme
David J. Jackson, Girolamo Pelaia, Benjamin Emmanuel, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 1, pp. 2301521-2301521
Open Access | Times Cited: 19
Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy
Hiroyuki Nagase, Maho Suzukawa, Keiji Oishi, et al.
Allergology International (2022) Vol. 72, Iss. 1, pp. 11-23
Open Access | Times Cited: 58
Biologics for severe asthma—Which, when and why?
Peer Ameen Shah, Christopher E. Brightling
Respirology (2023) Vol. 28, Iss. 8, pp. 709-721
Open Access | Times Cited: 27
Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient
Linda Rogers, Miloš Jeseňák, Leif Bjermer, et al.
Respiratory Medicine (2023) Vol. 218, pp. 107414-107414
Open Access | Times Cited: 25
Asthma Care in the Elderly: Practical Guidance and Challenges for Clinical Management - A Framework of 5 “Ps”
Jaskiran K. Khosa, Samuel Louie, Pamela Lobo Moreno, et al.
Journal of Asthma and Allergy (2023) Vol. Volume 16, pp. 33-43
Open Access | Times Cited: 22
How I do it. Choosing the right biologic for the right patient with severe asthma
Simon Couillard, David J. Jackson, Ian Pavord, et al.
CHEST Journal (2024)
Open Access | Times Cited: 8
Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and NSAID‐exacerbated respiratory disease
Xinni Xu, Sietze Reitsma, De Yun Wang, et al.
Allergy (2022) Vol. 77, Iss. 12, pp. 3593-3605
Closed Access | Times Cited: 29
Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making
Josje Janna Otten, Rik Johannes Leonardus van der Lans, Eugenio De Corso, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 8, pp. 1041-1049
Open Access | Times Cited: 21
Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
Wenjia Chen, Trung N. Tran, Mohsen Sadatsafavi, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 9, pp. 2732-2747
Open Access | Times Cited: 18
Switching Biological Therapies in Severe Asthma
Giulia Scioscia, Santi Nolasco, Raffaele Campisi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9563-9563
Open Access | Times Cited: 16
Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study
Masao Yamaguchi, Yoshihiro Nishimura, Y Takumi, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 45-60
Open Access | Times Cited: 6
Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both
Paul Pfeffer, Nasloon Ali, Ruth Murray, et al.
Allergy (2023) Vol. 78, Iss. 7, pp. 1934-1948
Open Access | Times Cited: 15
Real-World Data on Tezepelumab in Patients With Severe Asthma in Germany
Leonie Biener, Carlo Mümmler, Christopher Alexander Hinze, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 9, pp. 2399-2407.e5
Closed Access | Times Cited: 5
Biologics in severe asthma: a state-of-the-art review
Bishal Gyawali, Steve N. Georas, Sandhya Khurana
European Respiratory Review (2025) Vol. 34, Iss. 175, pp. 240088-240088
Open Access
The Department of Medical Sciences of the RAS, Therapeutic Sciences Council meeting: Scientific projects marathon of Russian therapeutic departments "From innovative technologies and education to healthcare practice. Pulmonology: from real clinical practice to promising developments"
О. М. Драпкина, С. Н. Авдеев, Е. К. Beltyukov, et al.
CARDIOVASCULAR THERAPY AND PREVENTION (2025) Vol. 23, Iss. 12, pp. 4289-4289
Open Access
Recent evidence for stepping down severe asthma therapies
Eric Merrell, Sandhya Khurana
Current Opinion in Pulmonary Medicine (2025)
Closed Access
Real-World Biologic Use Patterns in Severe Asthma, 2015–2021: The CLEAR Study
Trung N. Tran, Stephanie Chen, Benjamin Emmanuel, et al.
Pragmatic and Observational Research (2025) Vol. Volume 16, pp. 51-66
Open Access
Long-term, real-world effectiveness of biologics for severe uncontrolled asthma: The PROSPECT study
Kazuhisa Asai, Takashi Iwanaga, Mai Takahashi, et al.
Respiratory Investigation (2025) Vol. 63, Iss. 3, pp. 444-452
Open Access
Evaluation of Long-Term Response to Biological Therapy in Severe Asthma and Considerations for Treatment Adjustment
Jordan Giordani, Alessandro Pini, Laura Pini
Journal of Clinical Medicine (2025) Vol. 14, Iss. 8, pp. 2623-2623
Open Access
Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2
Donna Carstens, Diego J. Maselli, Mu Fan, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 7, pp. 2150-2161.e4
Closed Access | Times Cited: 12
Unanswered questions on the use of biologics in pediatric asthma
Antonio Nieto, Zeinab A. El-Sayed, René Maximiliano Gómez, et al.
World Allergy Organization Journal (2023) Vol. 16, Iss. 11, pp. 100837-100837
Open Access | Times Cited: 11
Efficacy of omalizumab after discontinuation: a retrospective single-center observational study in children with severe asthma
Simone Foti Randazzese, Cecilia Lugarà, Francesca Galletta, et al.
Frontiers in Allergy (2025) Vol. 6
Open Access
Biologics for severe asthma and beyond
Carlo Mümmler, Katrin Milger
Pharmacology & Therapeutics (2023) Vol. 252, pp. 108551-108551
Closed Access | Times Cited: 9
Recent advances in understanding the role of eosinophils
Gregory Constantine, Amy D. Klion
Faculty Reviews (2022) Vol. 11
Open Access | Times Cited: 14
Adult Severe Asthma Registries: A Global and Growing Inventory
Breda Cushen, Mariko Siyue Koh, Trung N. Tran, et al.
Pragmatic and Observational Research (2023) Vol. Volume 14, pp. 127-147
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top